ANC5C neurotoxicity

An Alzheimer’s disease-linked rare mutation potentiates netrin receptor uncoordinated-5C-induced signaling that merges with amyloid β precursor protein signaling

Yuichi Hashimoto¹, Yuka Toyama¹, Shinya Kusakari¹, Mikiro Nawa¹
Masaaki Matsuoka¹²

1, Department of Pharmacology, Tokyo Medical University
6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan
2, Department of Dermatological Neuroscience
6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan

Running title: UNCC5 neurotoxicity

Corresponding author: Masaaki Matsuoka, Department of Pharmacology and Dermatological Neuroscience, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.
Tel: 81-3-3351-6141, Fax: 81-3-3352-0316, Email: sakimatu@tokyo-med.ac.jp

Key words: UNC5C, neuronal death, netrin, Alzheimer’s disease

ABSTRACT A missense mutation (T835M) in the uncoordinated-5C (UNC5C) netrin receptor gene increases the risk of late-onset Alzheimer’s disease (AD) and also the vulnerability of neurons harboring the mutation to various insults. The molecular mechanisms underlying T835M-UNC5C-induced death remain to be elucidated. In our present study, we show that overexpression of wild-type UNC5C causes low-grade death, which is intensified by an AD-linked mutation T835M. An AD-linked survival factor CLSP and a natural ligand of UNC5C, netrin1, inhibit this death. T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death-signaling cascade, consisting of death-associated protein kinase 1/protein kinase D/ apoptosis signal-regulating kinase 1 (ASK1)/JNK/NADPH oxidase/caspases, which merges at ASK1 with a death-signaling cascade, mediated by amyloid β precursor protein (APP). Notably, netrin1 also binds to APP and partially inhibits the death-signaling cascade, induced by APP. These results may provide a new insight into the amyloid β-independent pathomechanism of AD.
Alzheimer’s disease (AD) is the most prevalent form of late-onset dementia. The upregulation of amyloid β (Aβ), which is deposited as an aggregate in senile plaques and forms soluble oligomers in the central nervous system (CNS), is considered to be a hallmark of AD and numerous studies showed its close relationship with the AD pathogenesis (1-3). Multiple missense mutations in three genes, Aβ precursor protein (APP), presenilin 1 (PS1), and PS2, cause autosomal-dominant familial AD. A number of studies have shown that constitutive expression of these mutant genes causes an increased production of Aβ and/or a increased ratio of Aβ42, a longer and more toxic isoform of Aβ, to Aβ40 in cells and that transgenic overexpression of these genes causes the formation of senile plaques and dementia in aged mice (2, 4). If used as potential AD drugs in mouse AD models, some Aβ antibodies eliminate Aβ from the CNS and some inhibitors to β- or γ-secretase reduce the production of Aβ in the CNS, thereby mitigating the dementia of these mice (2, 3). Despite these findings, there is still no direct evidence that Aβ causes neuronal toxicity in human AD patients. Although some ongoing clinical trials may be showing promise, the Aβ-reducing therapy has not been proved to be effective in human AD patients until now (5, 6).

Aβ-independent neurotoxicity may contribute to the pathogenesis of AD (7-9 for review). Overexpression of a London-type APP mutant V642I-APP or the binding of TGFβ2 to the extracellular domain of wild-type APP (wt-APP) causes neuronal cell death. These are mediated by a cell death-signaling pathway, consisting of heterotrimeric G protein Go, Rac1 or Cdc42, apoptosis signal-regulating kinase 1 (ASK1), JNK, NADPH oxidase, and caspases, independently of the production of Aβ (10-13).

It was recently reported that a missense mutation of a single spanning transmembrane protein uncoordinated-5 homologue C (UNC5C; alternative name UNC5H3), a netrin receptor (14-16 for review), increases the risk of late-onset AD (17), although the prevalence of its mutation in AD patients is low (17). Interestingly, T835M-UNC5C did not increase the production of Aβ but increased the vulnerability of neuronal cells to various insults (17). The molecular mechanism underlying T835M-UNC5C-mediated increase in neuronal toxicity remains uncharacterized.

The netrins and its receptors, UNC5 family proteins, are involved in axonal guidance during embryonal development.
UNC5C neurotoxicity

UNC5C and its close relatives UNC5A (UNC5H1), UNC5B (UNC5H2), and UNC5D (UNC5H4) are also known to be “dependence receptors”, which cause cell death in the absence of their ligands (14-16). There have been few studies on the molecular mechanisms underlying UNC5 family protein-induced cell death. It was shown in a previous study that UNC5A induces apoptosis by interacting with neurotrophin receptor-interacting melanoma-associated antigen homologue (18). Overexpression of UNC5B induces neuronal death by activating death-associated protein kinase (DAPK1) (19) via protein phosphatase A2-mediated dephosphorylation of DAPK1 (20).

In our present study, overexpression of T835M-UNC5C causes overt death in the absence of other neurotoxic insults while overexpression of wt-UNC5C causes low-grade death in F11 neurohybrid cells and SH-SY5Y neuroblastoma cells. A natural ligand for UNC5C, named netrins, and an endogenous AD-linked survival factor calmodulin-like skin protein (CLSP) inhibit this death. Our data also indicate that the T835M-UNC5C-induced neuronal cell death is mediated by an intracellular death signaling pathway, consisting of DAPK1/protein kinase D (PKD)/ASK1/JNK/NADPH oxidase/caspases.

EXPERIMENTAL PROCEDURES

Protein analysis-----For analysis of cell lysates, cells were washed twice with PBS and suspended in 50 mM HEPES (pH 7.4), 150 mM NaCl, 0.1% NP-40, and protease inhibitor cocktail Complete (Roche Diagnostics, Alameda, CA). After freezing and thawing twice, the cell lysate was centrifuged at 15,000 rpm for 10 min at 4°C. The supernatant was submitted to immunoprecipitation with an indicated antibody and/or analysis with standard or Tris-Tricine SDS polyacrylamide gel electrophoresis (SDS-PAGE) and/or immunoblot analysis. For immunoprecipitation, supernatants were mixed with the antibody and incubated at 4°C for 2 h, and then mixed at 1:1 with slurry of Protein G sepharose 4B (GE Healthcare, Little Chalfont, United Kingdom), and then rotated overnight before washing with the buffer. The whole washed precipitates were boiled in the SDS sample buffer before the application to the gels. Ten µg of cell lysates per lane were used for direct immunoblot analysis.

Recombinant proteins, antibodies, and other reagents-----GST-mouse CLSP1 (mCLSP1)-MycHis and GST-human CLSP
(hCLSP)-MycHis was expressed in *E. coli* BL-21 at 25°C for 6 h in 1 mM isopropyl-thio-β-D-galactopyranoside. Purified GST-mCLSP1-MycHis, bound to Glutathione Sepharose (GE Healthcare), was co-incubated in PBS containing thrombin (1 unit/ml, GE Healthcare) at 25°C overnight to be released from GST that bound to the Glutathione Sepharose, as shown previously (21). Recombinant GST protein was also purified for the usage as a negative control.

Recombinant mouse netrin1 was purchased from R&D Systems (catalogue no. 1109-N1/CF, Minneapolis, MN). Recombinant human transforming growth factor β2 (TGFβ2) was purchased from PeproTech EC (catalogue no. 100-358, London, UK). A DAPK1 inhibitor (catalogue no. 324788-10MGCN) and a PKD inhibitor (catalogue no. 476495-10MGCN) were purchased from Calbiochem-Novabiochem (San Diego, CA). An NADPH oxidase inhibitor acetovanillone (or apocynin) (catalogue no. W508454-100G) and a caspase-3 inhibitor Ac-DEVD-CHO (DEVD) (catalogue no. 3172-v) were purchased from Sigma-Aldrich (St. Louis, MO) and Peptide Institute (Osaka, Japan), respectively. TALON metal resin was purchased from Clontech (catalogue no. 635502, Mountain View, CA). Antibodies against indicated peptides and proteins used in this study were purchased from the following companies: horseradish peroxidate conjugated FLAG epitope (clone M2, catalogue no. 158592-1MG) and DAPK1 (catalogue no. WH0001612M1-100UG), Sigma-Aldrich (St. Louis, MO); APP (22C11, catalogue no. MAB348) and PS1 (catalogue no. MAB1563), Chemicon (Temecula, CA); phosphoSAPK/JNK (T183/Y185) (clone 81E11, catalogue no. #4668S) and protein kinase D (PKD, catalogue no. #2052S), Cell Signaling Technology (Beverly, MA); JNK (catalogue no. SC-571, Santa Cruz Biotechnology (Santa Cruz, CA); peroxidase conjugated HA epitope (clone 3F10, catalogue no. 2013819), Roche Diagnostics; and myc epitope (catalogue no. R950-25), Invitrogen (Carlsbad, CA).

**Genes and vectors-----** The pHA vector, a CMV promoter-driven expression vector harboring a C-terminally HA-tag, was generated as follows. The *in vitro* annealed sense primer, 5’-GCCCAGACCACCATGTACCCATACGAGGTACCCCGTCGTTCAGATTACGAGGAGTACCCGC-3’, and the antisense primer, 5’-CGGGGTACCTCAAGCGTAATCTGGAACTCGTATGGGTACATGGTGGTACCGGC-3’, encoding the HA epitope, was inserted into the pFLAG-5a vector (Eastman
Kodak, NY), at the KpnI site. A pRK5 expression vector encoding human wild-type (wt)UNC5C C-terminally tagged with HA was a gift from Dr. Guofa Liu (University of Toledo, Toledo, OH). As a control vector for the pRK5-wtUNC5C and -mutant UNC5C constructs, the empty pHA vector was used as it shares the basic components of plasmids. Human DAPK1 and K42A-DAPK1 (dominant-negative DAPK1) cDNAs inserted in the pRK5/Myc vector were gifts from Dr. T.H. Lee (Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA). HA-tagged human wtPKD (ID: 10808), constitutively active (S738E/S742E) PKD (ID: 10810), and kinase-dead (K612W) PKD (ID: 10809) in the pcDNA3 vector (Invitrogen) were purchased from Addgene (Tokyo, Japan). The T835M mutant of UNC5C was constructed using KOD-Plus-Mutagenesis Kit (Toyobo, Tokyo, Japan) with the sense primer, 5’-TGGTCACGGGGCCCAGTGCTTTCAGCATCCCTCTCCCTATCC-3’, and the antisense primer, 5’-TGGTGATGGTGTTCGCAGGATCCAGCAGCGGCAAATCGATGCC-3’. Death domain-defective UNC5C (wtUNC5CΔDD) and T835M-UNC5CΔDD were also constructed using the same kit with the sense primer, 5’-CAGTATCTCGAGGCGCTACCATACGATGTTCCTGACTATGCG-3’, and the antisense primer, 5’-CGTGACCGTGAGTGGTGTTCGCAGGATCCAGCAGCGGC-3’ and 5’-CGTGACCATGGTGATGGTGTTCGCAGGATCCAGCAGCGGC-3’, respectively. pRK5-FLAG-HA encoding mouse full-length mouse netrin1 (mNetrin1) was generously donated by Dr. Marko Hyttinen (The Haartman Institute, Translational Cancer Biology Research Program and Helsinki University Hospital, University of Helsinki). The mNetrin1 cDNA was inserted into the pEF1/MycHis vector (Invitrogen) at the EcoRI and XbaI sites. Mouse wtAPP and V642I-APP cDNAs inserted in the pcDNA3.1/MycHis were described previously (11-13). The expression vectors for dominant-negative ASK1 and JNK were also described in earlier studies (11-13).

**Cells, cell death, and cell viability**---Neuronal cell death assays related to AD were first performed by Yamatsuji et al. (10) and previously described in detail (11-13, 21). Neurohybrid F11 cells were also described earlier (22). F11 cells are the hybrids of rat embryonic day 13 primary cultured neurons and mouse neuroblastoma NTG18 cells. The transient transfection procedure was described previously in detail (10-13, 21). F11 cells,
seeded at $7 \times 10^4$/well in six-well plates in Ham's F12 with 18% FBS (HyClone™, GE Healthcare) for 12–16 h, were co-transfected with indicated vectors for 3 h in the absence of serum and were then incubated with Ham's F12 with 18% FBS for 2 h. Doses of transfected vectors were 0.5 µg unless otherwise mentioned. At 5 h after the onset of the transfection, culture media were replaced by Ham's F12 with 10% FBS. At 24 h after the transfection, the media were replaced by Ham's F12 containing N2 supplement (Invitrogen) with or without recombinant Netrin1, CLSP1, or TGFβ2. BSA (Sigma-Aldrich) or GST was used as negative controls. At 72 h after the onset of the transfection, the cells were harvested for the cell viability assays using the WST-8 cell death assay kit (Dojindo, Kumamoto, Japan) or the staining with calcein AM (Dojindo), and Trypan blue exclusion death assays with their microscopic views taken to show viable cells that were attached to cell plates, as described previously (13, 21, 23).

SH-SY5Y cells were grown in DMEM/Ham's F12 mixture (DMEM/F12) containing 10% FBS. SH-SY5Y cells were seeded at $2 \times 10^5$/well in six-well plates for 12–16 h, transfected with indicated vectors for 3 h in the absence of serum, and then cultured in DMEM/F12-10% FBS with/without a rescue factor. At 24 h after the transfection, the media were replaced with DMEM/F12 containing N2 supplement with/without a rescue factor. At 48 h after the onset of the transfection, cells were harvested to perform cell viability assays using the staining with calcein AM (Dojindo) and Trypan blue exclusion cell mortality assays (23).

Transfection efficiency in F11 cells and SH-SY5Y cells was approximately 80%.

COS 7 cell were grown in DMEM with 10% FBS and used only for the generation of recombinant mouse netrin1 C-terminally tagged with MycHis.

**In vitro binding assays by co-immunoprecipitation---**APP, UNC5C, its derivative, or Myc-DAPK1 was overexpressed in F11 cells by transfection. At 24 h after transfection, the cells were harvested for the preparation of cell lysates. Two types of cell lysates were mixed and incubated at 4°C overnight. The mixed cell lysates was then subjected to immunoprecipitation with a myc antibody.

**In vitro binding assays by pull-down---**APP, UNC5C, or mouse netrin1 was overexpressed in F11 cells or COS7 cells by transfection. At 24 h after transfection of pHA-wtAPP or pRK5-wtUNC5C to F11 cells, the F11 cells were harvested for the
preparation of cell lysates. At 48 h after transfection of pEF1/MycHis-mNetrin1 to COS7 cells, the conditioned media were also harvested for the pull-down with TALON metal beads (Clontech) that bind to the C-terminally 6xHis tagged mNetrin1. The washed TALON beads were then mixed with one of the cell lysates from the F11 cells and incubated at 4°C overnight. The mixtures were then subjected to extensive washing. The washed precipitates, the cell lysates, and the beads were then subjected to SDS-PAGE and immunoblot analysis.

In Vitro JNK Kinase Assays-----F11 cells, co-transfected with the pcDNA3-FLAG-JNK-1a1 construct with other vectors, were harvested at 48 h after transfection and lysates were prepared from these cells. The FLAG-JNK-1a1 protein expressed in the lysates was then immunoprecipitated with the FLAG antibody (M2). The immunoprecipitates were used for an in vitro JNK kinase assay using a recombinant c-Jun protein as a substrate, in accordance with the manufacturer’s instruction (KinaseSTAR JNK Activity Assay Kit, BioVision Research Products), and as described earlier (23). In brief, whole mixtures from the in vitro JNK kinase assay reactions were fractionated with SDS-PAGE and the levels of phosphorylated FLAG-JNK-1a1, total FLAG-JNK-1a1, and phosphorylated c-Jun (phospho c-Jun) were analyzed by immunoblot analysis with antibodies against phospho JNK, FLAG, and phospho c-Jun.

Statistical analysis-----All cell-death experiments were performed in triplicate (N=3). All values shown in the figures are the mean±SD. Statistical analysis was performed using one-way analysis of variance, followed by Bonferroni/Dunn post hoc analysis. Data densitometrically obtained using the ImageJ software were analyzed with Student’s t-test. All data were analyzed using StatView (version 5.0.1) software from SAS Institute (Cary, NC).

RESULTS

The T835M mutation intensifies the UNC5C-induced neuronal death that is inhibited by netrin1

The UNC5 family proteins are so-called dependence receptors that induce cell death in the absence of ligand binding (14-16). We found that overexpression of wt-UNC5C caused death in F11 neurohybrid cells (Figs. 1A-C). Notably, the T835M mutation intensified the wtUNC5C-induced death (Figs. 1A and B). As expected, recombinant
mouse netrin1 (mNetrin1) inhibited the wt-UNC5C- and the T835M-UNC5C-induced death (Figs. 1A and B) (14-16). This finding indicates that netrin1 may suppress the UNC5C-induced death by binding to UNC5C on the cell surface and inhibiting the UNC5C-mediated intracellular death signaling. Unexpectedly, however, owing to yet unknown mechanism, the treatment of these cells with netrin1 decreased wtUNC5C and T835M-UNC5C expression levels (Fig. 1C). This finding indicates that it is also possible that netrin1 may reduce the UNC5C-induced death by decreasing the levels of UNC5C. To confirm that the former mechanism contributes to the netrin-induced inhibition of the T835M-UNC5C-induced death, we performed another experiment in which the levels of UNC5C expression were changed by the alteration of doses of the transfected UNC5C vectors (Figs. 1D-F). Transfection of 0.25 µg of the T835M-UNC5C-encoding vector, followed by the mock incubation, and transfection of 0.5 µg of the T835M-UNC5C-encoding vector, followed by the incubation with recombinant netrin1, resulted in similar protein expression levels of T835M-UNC5C (Fig. 1F, lanes 5 and 8). The former transfection caused cell death while the latter transfection did not cause apparent cell death (Figs. 1D and E, columns 5 and 8). This result indicates that netrin1 inhibited the UNC5C-induced death by binding to UNC5C on the cell surface and inhibiting the UNC5C-mediated intracellular death signaling.

CLSP inhibits the T835M-UNC5C-induced death in F11 and SH-SY5Y cells.

It was previously shown that neuronal death induced by a London-type familial AD-linked APP mutant V642I-APP or the binding of TGFβ2 to the extracellular domain of wtAPP is mediated by heterotrimeric G protein Go, Rac1 or Cdc42, ASK1, JNK, NADPH oxidase, and caspases in vitro (10-13). Humanin and CLSP are secreted bioactive peptides that inhibit AD-related neuronal death (24) by binding to a heterotrimeric humanin receptor (25, 26) and by inducing expression of SH3BP5, a newly identified endogenous JNK inhibitor (23). In our current study, we assessed whether recombinant CLSP is effective against another intracellular signaling pathway underlying the AD-linked neuronal death, induced by overexpression of T835M-UNC5C, and found that recombinant mouse CLSP1 (mCLSP1) (27) completely inhibited the T835M-UNC5C-induced death (Figs. 2A-C). This result suggests that the T835M-UNC5C-induced death signaling is also mediated by JNK because JNK is the
target of the CLSP-induced survival signaling.

Using another neuronal cells, SH-SY5Y cells, we further confirmed that overexpression of T835M-UNC5C induced neuronal cell death and that the T835M-UNC5C-induced neuronal cell death was inhibited by the treatment with recombinant mouse netrin1 and human CLSP (Figs. 2D-F).

The T835M-UNC5C-induced death is mediated by DAPK1 and PKD

A previous study (19) has reported that overexpression of UNC5B causes cell death by binding to and activating DAPK1 via its death domain. The same study additionally showed that UNC5C also showed weak binding to DAPK1 (19). In our current study, the deletion of the C-terminal death domain of UNC5C (UNC5C∆DD) markedly attenuated the T835M-UNC5C-induced death (Figs. 3A-C). Furthermore, co-immunoprecipitation analysis revealed that DAPK1 bound to UNC5C whereas DAPK1 did not bind to UNC5C if UNC5C lacked the death domain (Fig. 3D), suggesting that UNC5C is associated with DAPK1 via its death domain and that the interaction of UNC5C with DAPK1 is responsible for the UNC5C-induced death. These findings prompted us to examine whether the UNC5C-induced death is mediated by DAPK1. We treated the cells overexpressing T835M-UNC5C with a DAPK1 inhibitor and found that this treatment almost nullified the T835M-UNC5C-induced death (Figs. 4A-C). Moreover, co-expression of a dominant-negative DAPK1 (dnDAPK1) inhibited the T835M-UNC5C-induced death (Figs. 4D and E). These results together indicate that DAPK1 mediates the UNC5C-induced death.

It was previously reported that under the oxidative stress condition, DAPK1 binds to and phosphorylates PKD, and that PKD is indispensable for the DAPK1-induced JNK phosphorylation (28). Considering these findings (28) and our current findings, shown above (Fig. 2), that CLSP inhibits the T835M-UNC5C-induced cell death, possibly by inactivating JNK (23), we hypothesized the involvement of PKD and JNK in the UNC5C-induced death-signaling pathway. In our current study we first examined the involvement of PKD. The treatment of the cells overexpressing T835M-UNC5C with a PKD inhibitor (Figs. 4A-C) and the co-overexpression of a kinase-dead PKD (kdPKD) almost completely inhibited the T835M-UNC5C-induced death (Figs. 4D and E). These results indicate that PKD participates in the T835M-UNC5C-induced death.
death as a downstream mediator of DAPK1.

**ASK1 and JNK are involved in the T835M-UNC5C-induced death-signaling pathway as downstream mediators of PKD**

We next examined the involvement of JNK as well as ASK1, an upstream MAP kinase of JNK (11-13), in the T835M-UNC5C-induced death. Co-expression of a dominant-negative ASK1 or JNK almost completely inhibited the T835M-UNC5C-induced death (Figs. 5A and B). This result suggests that ASK1 and JNK mediate the T835M-UNC5C-induced neuronal death.

To confirm the involvement of PKD, ASK1, and JNK in the T835M-UNC5C-induced death, we overexpressed constitutively active PKD (caPKD) with or without dominant-negative JNK or ASK1 (dnJNK or dnASK1) in F11 cells. Expression of caPKD caused death in F11 cells, similarly to that of T835M-UNC5C, and the caPKD-induced death was largely blocked by co-expression of dnASK1 or dnJNK (Figs. 6A and B). This result supports the idea that ASK1 and JNK mediate the T835M-UNC5C-induced death-signaling pathway as downstream mediators of PKD.

To further confirm the involvement of JNK in the T835M-UNC5C-induced death, we expressed FLAG-JNK1a1 alone or in association with T835M-UNC5C or V642I-APP in F11 cells and immunoprecipitated FLAG-JNK1a1 from the cell lysates. These immunoprecipitates were then used for *in vitro* JNK kinase assays with c-Jun-derived peptide as a substrate (Fig. 6C) (23). Co-expression of T835M-UNC5C or V642I-APP increased the levels of phosphorylated FLAG-JNK1a1 and phosphorylated c-Jun (Fig. 6C). This result supported our notion that JNK mediates the T835M-UNC5C-induced as well as the V642I-APP-induced death-signaling pathway (10-13).

The T835M-UNC5C-induced death-signaling pathway is mediated by NADPH oxidase and caspases

As downstream mediators, NADPH oxidase and caspases were shown previously to be involved in the neuronal death induced by V642I-APP or by the binding of TGFβ2 to the extracellular domain of wtAPP (11-13). In our present analyses, treatment with the NADPH oxidase inhibitor apocynin or the caspase-3 inhibitor DEVD almost completely inhibited the T835M-UNC5C-induced neuronal cell death (Figs. 7A-C). This result indicates that these mediators are also involved in the pathway, possibly as a downstream mediator of JNK.
The T835M-UNC5C-induced death-signaling pathway merges with the APP-mediated death-signaling pathway at ASK1

Thus, in our current study, we have demonstrated that the T835M-UNC5C-induced neuronal death is mediated by DAPK1, PKD, ASK1, JNK, NADPH oxidase, and caspases. In previous studies (11-13), it was shown that the V642I-APP-induced neuronal cell death and the TGFβ2-induced neuronal death via APP are mediated by a heterotrimeric GTP-binding protein Go, Rac1/Cdc42, ASK1, JNK, NADPH oxidase, and caspases. Comparing these results, we could assume that both death signals advance independently during the initial phase, merge at ASK1, and progress via a common death-signaling pathway, mediated by JNK/NADPH oxidase/caspases, during the final phase. Considering that DAPK1 and PKD act as upstream mediators of ASK1 in the former signal transduction pathway, we further examined the possibility that DAPK1 and PKD also participate in the latter signal transduction pathway as an upstream mediator of ASK1. However, the treatment of the cells overexpressing V642I-APP with the DAPK1 or PKD inhibitor did not affect the V642I-APP-induced neuronal death (Figs. 8A-C). This result indicated that neither DAPK nor PKD is involved in the latter signal transduction pathway.

UNC5C neurotoxicity

Netrin1 binds to APP and partially attenuates the TGFβ2-induced death via APP

It was previously shown that netrin1 also binds to a domain of APP containing the Aβ-corresponding region and decreases the production of Aβ (29). In our current study, we confirmed that netrin1 binds to APP (Fig. 9A). Considering these findings, we further examined whether netrin1 affects the APP-mediated neuronal cell death, triggered by the binding of TGFβ2 to APP (11, 30). As shown in previous studies (11-13), TGFβ2 treatment induced death in F11 cells overexpressing wtAPP (Figs. 9B and C). In contrast, the netrin1 treatment did not induce death in F11 cells overexpressing wtAPP (Figs. 9B and C). Notably, however, the netrin1 treatment decreased the TGFβ2-induced neuronal cell death via APP significantly albeit incompletely (Figs. 9B and C). These results indicated that netrin1 inhibits the APP-mediated neuronal cell death as well as the UNC5C-induced neuronal cell death.

DISCUSSION

The death-signaling pathway underlying the UNC5C-induced cell death has not been previously characterized. This is possibly because UNC5C induces cell death
only weakly \textit{in vitro} (Fig. 1). However, the AD-linked T835M mutation greatly increases the toxicity by UNC5C (Fig. 1), enabling us to characterize the death-signaling pathway by UNC5C in detail \textit{in vitro} in our current analyses.

The percentages of dead F11 cells and SH-SY5Y cells that were transfected with the T835M-UNC5C-encoding vector were approximately 50% in the current study (Figs. 1-3) whereas the percentages of dead HEK293T cells and primary rat hippocampal neurons that exogenously expressed T835M-UNC5C were approximately 25% and 50% at the harvest time in the previous study (17). Given the transfection efficiency in our experiments using F11 cells and SH-SY5Y cell is 80% or more, the death-inducing activity of T835M-UNC5C is estimated to be slightly higher in our neuronal cell lines than in those reported previously (17).

In our current study, DAPK1 was first found to interact with and be activated by UNC5C (Figs. 3 and 4). DAPK1 belongs to the DAP calmodulin-regulated serine/threonine kinase family, whose members include DAPK1, DRP-1, and ZIP kinase. Although DAPK1 is involved in a variety of caspase-dependent and -independent cell death as well as autophagy (31), its downstream mediators have not been sufficiently characterized (32). Until now, only one study addressed to the DAPK1-mediated cell death-signaling pathway (28), showing that the DAPK1-mediated cell death-signaling pathway during oxidative stress is mediated by PKD and JNK. In our current study, we have shown that in the T835M-UNC5C-induced death, PKD works as a downstream mediator of DAPK1 (Fig. 4).

A series of experiments, the results of which are shown in Figs. 3-7, led us to conclude that the T835M-UNC5C-induced death-signaling pathway is composed of DAPK1/PKD/ASK1/JNK/NADPH oxidase/caspases.

Other uncharacterized signaling molecules may also be involved in the T835M-UNC5C-induced cell death. For example, a neurotrophin receptor-interacting melanoma-associated antigen (MAGE) homologue named NRAGE was previously identified as an UNC5A-interacting protein that mediates the UNC5A-induced death-signaling pathway in COS cells (18), possibly further mediated by the degradation of the caspase inhibitor X-chromosome-linked inhibitor of apoptosis protein and/or the activation of the JNK signalling pathway (18). Because the binding affinity of NRAGE to UNC5C appears to be much weaker than that to UNC5A (18), it is
less likely that NRAGE is a mediator of the T835M-UNC5C-induced death.

It remains undetermined whether PKD directly interacts with ASK1 in the signal transduction pathways. It is possible that some molecules such as Rac1/Cdc42 connect these components as intermediate mediators. If this is true, the merging point between the T835M-UNC5C-induced and the APP-mediated death-signaling pathways may move upstream of ASK1.

It is highly likely that humanin, CLSP, and netrins work as endogenous neuroprotective factors that suppress the AD-related neuronal toxicities. CLSP inhibits both the APP-mediated neuronal cell death (21, 24) and the UNC5C-mediated neuronal cell death (Fig. 2). Netrin1 inhibits the UNC5C-mediated neuronal cell death (Figs. 1 and 2) and partially inhibits the APP-mediated neuronal cell death (Fig. 9B) by binding to APP (Fig. 9A). In an earlier study, it was shown that netrins inhibit the production of Aβ (33). Based on these findings, it could be further assumed that the dysfunction of CLSP, humanin, or netrins may contribute to the AD pathogenesis.

The T835M-UNC5C-induced death-signaling pathway, mediated by DAPK1/PKD/ASK1/JNK/NADPH oxidase/caspases, merges at ASK1 with the APP-mediated death-signaling pathway which consists of Go/Rac1 or Cdc42/ASK1/JNK/NADPH oxidase/caspases (Fig. 11) (11-13). This finding suggests that the signal transduction pathway via ASK1/JNK/NADPH oxidase/caspases may be the common late-phase AD-linked cell death-signaling pathway. This notion is consistent with the results of multiple earlier in vivo studies using AD model mice and AD patient-derived brains. JNK is activated in the neurons of AD model mice (33 for review, 34-36) and AD patients (33 for review). NADPH oxidase is activated in the neurons of AD model mice and AD patients (37-39 for review). Multiple studies have also shown that the activation of caspases occurs in the brains of AD patients (40 for review). Interestingly, a study demonstrated that the expression of DAPK increased in the brains of some AD patients (41).

The mutant form of UNC5C is present as a risk factor (17) throughout the life whereas the disease occurs later in the life. The mechanism underlying the effect of aging on the disease onset remains to be investigated. It could be hypothesized that multiple other neuronal toxicities including Aβ must accumulate during aging to finally cause neuronal cell death. It is also possible that aging causes the deterioration of some endogenous protective systems that suppress
the disease onset in younger ages. Humanin-, CLSP-, and netrin-mediated inhibition of AD-related toxicities may be examples of such protective systems.

There is no direct linkage between the T835M mutation of UNC5C and the Aβ cascade hypothesis. Most importantly, the T835M mutation does not affect the production of Aβ (17). In addition, the T835M mutation not only increases the vulnerability of cells to Aβ but also to other insults in a similar manner (17). These findings indicate that the T835M-UNC5C-induced neuronal cell death occurs independently of Aβ and that this mutation may equally increase the risk for other neurodegenerative diseases. The latter possibility remains to be investigated. Our previous studies also suggest that the cell death-signaling pathway via APP, mediated by a heterotrimeric GTP-binding protein Go, Rac1/Cdc42, ASK1, JNK, NADPH oxidase, and caspases, appears to be independent of Aβ, because artificially mutated APP that does not generate Aβ, is still able to induce neuronal cell death (10-13).

Recently, a missense mutation in APP that is protective against AD was reported (13, 42). The AD-protective mutation not only reduces the production of Aβ (42) but also attenuates the APP-mediated intracellular death signal independently of the reduction of Aβ (13). Moreover, a mutation that causes hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D) also attenuates the APP-mediated intracellular death signal (13). HCHWA-D, in which amyloidosis occurs in both the vascular walls and the parenchyma of the brain and the rupture of arteries with massive amyloidosis causes stroke (43). Notably, AD-type neuronal death does not occur in HCHWA-D despite massive parenchymal amyloidosis (44). From the standpoint of neuronal cell death-signaling pathways that are dependent or independent of Aβ, the evidence suggests that the pathogenesis of AD should be reconsidered.

ACKNOLEDGMENT

We are grateful to Ms. Takako Hiraki and Ms. Tomoko Yamada for essential assistance throughout the study. We thank Dr. Guofa Liu, Dr. Tae Ho Lee, and Dr. Marko Hyytiäinen for expression vectors. This work was supported in part by the Grant-in-Aid for Scientific Research (B) [grant number 15H04689] to [M.M.] and Grant-in-aid for Scientific Research (C) [grant number 25460343] to [Y.H] from Japan Society for the Promotion of Science, by Naito Foundation Natural Science Scholarship to [M.M.], and by the research grant from Akaeda
UNC5C neurotoxicity

Medical Research Foundation to [M.M.].

COMPETING FINANCIAL INTERESTS

The authors declare that they have no competing financial interests.

CONTRIBUTION

Y.H., Y.T., S. K., and M. N. performed the experiments. Y.H. and M.M. designed the experiments and analyzed the data and wrote the manuscript. M.M. directed the study.

REFERENCES

1. Hardy, J., and Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356

2. Selkoe, D.J. (2011) Alzheimer's disease. Cold Spring Harb Perspect Biol 3 pii: a004457

3. Selkoe, D.J. (2013) SnapShot: pathobiology of Alzheimer's disease. Cell 154, 468-468

4. Chávez-Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., Wiltfang, J., Serneels, L., Karran, E., Gijsen, H., Schymkowitz, J., Rousseau, F., Broersen, K., and De Strooper, B. (2012) The mechanism of $\gamma$-secretase dysfunction in familial Alzheimer disease. EMBO J. 31, 2261-2274

5. Tayeb, H.O., Murray, E.D., Price, B.H., and Tarazi, F.I. (2013) Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? Expert Opin. Biol. Ther. 13, 1075-1084

6. Selkoe, D.J. (2013) The therapeutics of Alzheimer's disease: where we stand and where we are heading. Ann. Neurol. 74, 328-336
UNC5C neurotoxicity

7. Cruz, J.C., and Tsai, L.H. (2004) Cdk5 deregulation in the pathogenesis of Alzheimer's disease. *Trends Mol. Med.* **10**, 452-458

8. Mattson, M.P. (2007) Calcium and neurodegeneration. *Aging Cell* **6**, 337–350

9. Matsuoka, M. (2009) HUMANIN: A Defender against Alzheimer’s disease. *Recent Patents CNS Drug Discov.* **4**, 37-42

10. Yamatsuji, T., Matsui, T., Okamoto, T., Komatsuzaki, K., Takeda, S., Fukumoto, H., Iwatsubo, T., Suzuki, N., Asami-Odaka, A., Ireland, S., Kinane, T.B., Giambarella, U., and Nishimoto, I. (1996) G protein–mediated neuronal DNA fragmentation by familial Alzheimer’s disease associated V642 mutants of APP. *Science* **272**, 1349-1352

11. Hashimoto, Y., Chiba, T., Yamada, M., Nawa, M., Kanekura, K., Suzuki, H., Terashita, K., Aiso, S., Nishimoto, I., and Matsuoka M. (2005) Transforming growth factor β2 is a neuronal cell death-inducing ligand for amyloid-β precursor protein. *Mol. Cell. Biol.* **25**, 9304-9317

12. Tachi, N., Hashimoto, Y., and Matsuoka, M. (2012) MOCA is an integrator of the neuronal death signals that are activated by familial Alzheimer's disease-related mutants of amyloid β precursor protein and presenilins. *Biochem. J.* **442**, 413-422

13. Hashimoto Y, Matsuoka M. (2014) A mutation protective against Alzheimer's disease renders amyloid β precursor protein incapable of mediating neurotoxicity. *J. Neurochem.* **130**, 291-300

14. Arakawa, H. (2004) Netrin-1 and its receptors in tumorigenesis. *Nat. Rev. Cancer* **4**, 978-987

15. Moore, S.W., Tessier-Lavigne, M., and Kennedy, T.E. (2007) Netrins and their receptors. *Adv. Exp. Med. Biol.* **621**, 17-31
16. Larrieu-Lahargue, F., Thomas, K. R., and Li, D. Y. (2012) Netrin Ligands and Receptors: Lessons from neurons to the endothelium. *Trends Cardiovasc. Med.* **22**, 44–47

17. Wetzel-Smith, M.K., Hunkapiller, J., Bhangale, T.R., Srinivasan, K., Maloney, J.A., Atwal, J.K., Sa, S.M., Yaylaoglu, M.B., Foreman, O., Ortmann, W., Rathore, N., Hansen, D.V., and Tessier-Lavigne, M. (2014) A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. *Nat. Med.* **20**, 1452-1457.

18. Williams, M. E., Strickland, P., Watanabe, K., and Hinck, L. (2003) UNC5H1 induces apoptosis via its juxtamembrane region through an interaction with NARG. *J. Biol. Chem.* **278**, 17483–17490

19. Llambi, F., Lourenço, F. C., Gozuacik, D., Guix, C., Pays, L., Del Rio, G., Kimchi, A., and Mehlen, P. (2005) The dependence receptor UNC5H2 mediates apoptosis through DAP-kinase. *EMBO J.* **24**, 1192-1201

20. Guenebeaud, C., Goldschneider, D., Castets, M., Guix, C., Chazot, G., Delloye-Bourgeois, C., Eisenberg-Lerner, A., Shohat, G., Zhang, M., Laudet, V., Kimchi, A., Bernet, A., and Mehlen, P. (2010) The Dependence Receptor UNC5H2/B Triggers Apoptosis via PP2A-Mediated Dephosphorylation of DAP Kinase. *Mol. Cell* **40**, 863-876

21. Hashimoto, Y., Nawa, M., Kurita, M., Tokizawa, M., Iwamatsu, A., and Matsuoka, M. (2013) Secreted calmodulin-like skin protein inhibits neuronal death in cell-based Alzheimer's disease models via the heterotrimeric Humanin receptor. *Cell Death Dis.* **4**, e555

22. Platika, D., Boulos, M.H., Braizer, L., and Fishman, M.C. (1985) Neuronal traits of clonal cell lines derived by fusion of dorsal root ganglia neurons with neuroblastoma cells. *Proc. Natl. Acad. Sci. USA* **82**, 3499-3503
23. Takeshita, Y., Hashimoto, Y., Nawa, M., Uchino, H., and Matsuoka, M. (2013) SH3-binding protein 5 mediates the neuroprotective effect of the secreted bioactive peptide humanin by inhibiting c-Jun NH2-terminal kinase. *J. Biol. Chem.* **288**, 24691-24704

24. Matsuoka, M. (2015) Protective effects of Humanin and calmodulin-like skin protein in Alzheimer's disease and broad range of abnormalities. *Mol. Neurobiol.* **51**, 1232-1239

25. Hashimoto, Y., Kurita, M., Aiso, S., Nishimoto, I., and Matsuoka, M. (2009) Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor α/WSX-1/gp130. *Mol. Biol. Cell* **20**, 2864-2873

26. Matsuoka, M., and Hashimoto, Y. (2010) Humanin and the receptors for humanin. *Mol. Neurobiol.* **41**, 22-28

27. Hayashi, M., Tajima, H., Hashimoto, Y., and Matsuoka, M. (2014) Secreted calmodulin-like skin protein ameliorates scopolamine-induced memory impairment. *Neuroreport* **25**, 725-729.

28. Eisenberg-Lerner, A., and Kimchi, A. (2007) DAP kinase regulates JNK signaling by binding and activating protein kinase D under oxidative stress. *Cell Death Differ.* **14**, 1908–1915

29. Lourenc, F.C., Galvan, V., Fombonne, J., Corset, V., Llambi, F., Muller, U., Bredesen, D.E., and Mehlen, P. (2009) Netrin-1 interacts with amyloid precursor protein and regulates amyloid-β production. *Cell Death Differ.* **16**, 655–663

30. Bodmer, S., Podlisny, M.B., Selkoe, D.J., Heid, I., and Fontana, A. (1990) Transforming growth factor-β bound to soluble derivatives of the beta amyloid precursor protein of Alzheimer's disease. *Biochem. Biophys. Res. Commun.* **171**, 890-897

31. Shiloh, R., Bialik, S., and Kimchi, A. (2014) The DAPK family: a structure-function analysis. *Apoptosis* **19**, 286-297
32. Fujita, Y., and Yamashita, T. (2014) Role of DAPK in neuronal cell death. *Apoptosis* **19**, 339–345

33. Mehan, S., Meena, H., Sharma, D., and Sankhla, R. (2011) JNK: A Stress-Activated Protein Kinase Therapeutic Strategies and Involvement in Alzheimer's and Various Neurodegenerative Abnormalities. *J. Mol. Neurosci.* **43**, 376–390

34. Zhou, Q., Wang, M., Du, Y., Zhang, W., Bai M, Zhang, Z., Li, Z., and Miao, J. (2015) Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPsw/PStdE9 mice. *Ann. Neurol.* **77**, 637-654

35. Barbero-Camps, E., Fernández, A., Martinez, L., Fernández-Checa, J.C., and Colell, A. (2013) APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease. *Hum. Mol. Genet.* **22**, 3460-3476

36. Savage, M.J., Lin, Y.G., Ciallella, J.R., Flood, D.G., and Scott, R.W. (2002) Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. *J. Neurosci.* **22**, 3376-3385

37. Block, M. L. (2008) NADPH oxidase as a therapeutic target in Alzheimer's disease. *BMC Neuroscience* **9** (Suppl 2), S8

38. Ansari, M.A., and Scheff, S.W. (2011) NADPH-oxidase activation and cognition in Alzheimer's disease Progression. *Free Radic. Biol. Med.* **51**, 171–178

39. Hernandes, M. S., and Britto, L. R. G. (2012) NADPH Oxidase and Neurodegeneration. *Current Neuropsycharmacology* **10**, 321-327

40. Rohn, T.T. (2010) The role of caspases in Alzheimer's disease; potential novel therapeutic opportunities. *Apoptosis* **15**, 1403-1409
UNC5C neurotoxicity

41. Kim, B.M., You, M-H., Chen C-H., Lee, S., Hong, Y., Kimchi, A., Zhou, X.Z., and Lee, T.H. (2014) Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function. Cell Death Dis. 5, e1237

42. Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R.R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O.A., Jönsson, E.G., Palotie, A., Behrens, T.W., Magnusson, O.T., Kong, A., Thorsteinsdottir, U., Watts, R.J. and Stefansson, K. (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99

43. Levy, E., Carman, M.D., Fernandez-Madrid, I.J., Power, M.D., Lieberburg, I., van Duinen, S.G., Bots, G.T., Luyendijk, W., and Frangione, B. (1990) Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124–1126

44. Wattendorff, A.R., Frangione, B., Luyendijk, W., and Bots G.T. (1995) Hereditary cerebral haemorrhage with amyloidosis, Dutch type (HCHWA-D): clinicopathological studies. J. Neurol. Neurosurg. Psychiatry 58, 699-705

FOOTNOTES

Abbreviations: AD, Alzheimer’s disease; Aβ, amyloid beta; APP, amyloid β precursor protein; ASK1, apoptosis signal-regulating kinase 1; CNS, central nervous system; CLSP, calmodulin-like skin protein; CNS, central nervous system; DAPK1, death-associated protein kinase1; DEVD, Ac-DEVD-CHO; JNK, c-Jun-N-terminal kinase; PKD, protein kinase D; presenilin, PS; TGFβ2, transforming growth factorβ2; UNC5C, uncoordinated-5 C

FIGURE LEGENDS

Figure 1. Overexpression of UNC5C induces neuronal cell death, intensified by the T835M mutation but inhibited by the binding of netrin1.

(A-C) F11 cells, transfected with the empty pHA vector (vector), pRK5-wtUNC5C (wtUNC5C),
or pRK5-T835M-UNC5C (T835M-UNC5C), were co-incubated with or without 1.0 µM recombinant mouse netrin1 (mNetrin1) or bovine serum albumin (BSA) for 48 h. This co-incubation was started at 24 h after transfection. At 72 h after transfection, the cells were harvested for Trypan blue exclusion assays (A) and WST-8 assays (B). The cell lysates were subjected to SDS-PAGE and immunoblot analysis with the monoclonal antibody to HA (C).

**(D-F)** F11 cells, transfected with indicated amounts (µg/well) of the empty pHA vector (vector) or pRK5-T835M-UNC5C, were co-incubated with or without 1.0 µM recombinant mouse Netrin1 (mNetrin1) or BSA for 48 hr. The co-incubation was started at 24 hr after transfection. At 72 hr after transfection, they were harvested for Trypan blue exclusion assays (D) and WST-8 assays (E). The cell lysates were subject to SDS-PAGE and immunoblot analysis with a monoclonal antibody against HA (F). ***p < 0.001; **p < 0.01; n.s., not significant

**Figure 2. CLSP inhibits T835M-UNC5C-induced death in F11 cells and SH-SY5Y cells.**

**(A-C)** F11 cells, transfected with the empty pHA vector (vector) or pRK5-T835M-UNC5C, were co-incubated with or without 10 nM recombinant mouse CLSP1 (mCLSP1) or glutathione S-transferase (GST) as a negative control for 48 h. The co-incubation was started at 24 hr after transfection. At 72 hr after transfection, the cells were harvested for Trypan blue exclusion assays (A) and WST-8 assays (B). The cell lysates were subjected to SDS-PAGE and immunoblot analysis with a monoclonal antibody against HA (C).

**(D-F)** SH-SY5Y cells, transfected with the empty pHA vector (vector) or pRK5-T835M-UNC5C, were co-incubated with or without 1.0 µM recombinant mouse netrin1 (mNetrin1), 10 nM recombinant human CLSP (hCLSP1) or 1.0 µM BSA as a negative control for 48 h. The co-incubation was started at 24 hr after transfection. At 24 hr after transfection, the cells were harvested for Trypan blue exclusion assays (D) and calcein assays (E). The cell lysates were subjected to SDS-PAGE and immunoblot analysis with a monoclonal antibody against HA (F). ***p < 0.001; n.s., not significant

**Figure 3 The death domain of UNC5C is essential for UNC5C’s toxicity.**

**(A-C)** F11 cells, transfected with the empty pHA vector (vector), pRK5-T835M-UNC5C, or pRK5-T835M-UNC5CΔD, were harvested at 72 h after transfection for Trypan blue exclusion assays (A) and WST-8 assays (B). The cell lysates were then subjected to SDS-PAGE and immunoblot analysis with a monoclonal antibody against HA (C).

**(D)** F11 cells were
transfected with the pHA vector (vector), pHA-wtAPP (wtAPP), or pRK5-wtUNC5C (wtUNC5C), pRK5-wtUNC5CΔDD (wtUNC5CΔDD), the empty pRK5/Myc vector (Myc vector), or pRK5/Myc-DAPK1 (Myc DAPK1). At 24 h after transfection, the cells were harvested for the preparation of cell lysates. Two types of cell lysates were mixed and incubated at 4°C overnight. The mixed cell lysates were then subjected to immunoprecipitation using a myc antibody. Washed immunoprecipitates (IP with anti-myc) and the cell lysates (Input) were then subjected to SDS-PAGE and immunoblot analysis with a myc antibody or HA antibody. Overexpression of wt-APP was performed as a transfection control. ***p < 0.001; n.s., not significant.

**Figure 4. T835M-UNC5C-induced cell death is mediated by DAPK and PKD.**

(A-C) F11 cells, transfected with the empty pHA vector (vector) or pRK5-T835M-UNC5C, were co-incubated with or without 1 µM DAPK1 inhibitor or 1 µM PKD inhibitors (or DMSO as a negative control) for 48 h. This co-incubation was started at 24 h after transfection. At 72 h after transfection, the cells were harvested for Trypan blue exclusion assays (A) and WST-8 assays (B). The cell lysates were then subjected to SDS-PAGE and immunoblot analysis with a monoclonal antibody against HA (C). (D, E) F11 cells, co-transfected with the empty pHA vector (vector) or pRK5-T835M-UNC5C together with the empty pRK5/Myc vector (vector 1) or pRK5/Myc-dominant-negative DAPK1 (dnDAPK1) or with the empty pcDNA3 vector (vector 2) or pcDNA3-kinase-dead PKD (kdPKD), were harvested at 72 h for Trypan blue exclusion assays (D). The cell lysates were then subjected to SDS-PAGE and immunoblot analysis with a monoclonal antibody against HA or a DAPK1 antibody mixed with PKD antibody (E). ***p < 0.001; n.s., not significant.

**Figure 5. T835M-UNC5C-induced cell death is mediated by ASK1 and JNK.**

(A, B) F11 cells, were co-transfected with the empty pHA vector (vector) or pRK5-T835M-UNC5C together with the pcDNA3 vector (vector), pcDNA3-dominant-negative ASK1 (dnASK1) or pcDNA3-dominant-negative JNK (dnJNK). At 72 h, the cells were harvested for Trypan blue exclusion assays (A). The cell lysates were subjected to SDS-PAGE and immunoblot analysis with a monoclonal antibody against HA (B). ***p < 0.001; *p < 0.05; n.s., not significant.
**UNC5C neurotoxicity**

**Figure 6.** Constitutively active PKD induces cell death, mediated by ASK1 and JNK.

(A, B) F11 cells, were co-transfected with the empty pHA vector (vector) or pcDNA3-constitutively active PKD (caPKD) together with the pcDNA3 vector (vector2), pcDNA3-dominant negative ASK1 (dnASK1) or pcDNA3-dominant-negative JNK (dnJNK). At 72 h, the cells were harvested for Trypan blue exclusion assays (A). The cell lysates were subjected to SDS-PAGE and immunoblot analysis with a PKD antibody or a monoclonal antibody against HA (B). (C) F11 cells were co-transfected with pcDNA3-FLAG-JNK1a1 and the empty pHA vector (vector), pRK5-T835M-UNC5C or pHA-V642I-APP. At 48 h after transfection, the cells were harvested for the preparation of cell lysates. FLAG-JNK1a1 in the lysates was immunoprecipitated with a FLAG antibody (M2) and used for *in vitro* kinase assays with c-Jun-derived peptide as a substrate. Whole mixtures were subjected to SDS-PAGE and immunoblot analysis with a HA antibody, phospho c-Jun antibody, phospho JNK antibody, or FLAG antibody (M2). Similar results were obtained in three independent experiments. ***p < 0.001; n.s., not significant.

**Figure 7.** NADPH oxidase and caspases are involved in cell death, mediated by T835M-UNC5C.

(A-C) F11 cells, transfected with the empty pHA vector (vector) or pRK5-T835M-UNC5C, were co-incubated with or without 100 μM NADPH oxidase inhibitor acetovanillone (or apocynin; APO) or 100 μM caspase-3 inhibitor Ac-DEVD-CHO (DEVD) for 48 h. This co-incubation was started at 24 h after transfection. At 72 h after transfection, the cells were harvested for Trypan blue exclusion assays (A) and WST-8 assays (B). The cell lysates were subjected to SDS-PAGE and immunoblot analysis with a monoclonal antibody against HA (C). ***p < 0.001; n.s., not significant.

**Figure 8.** Neither DAPK1 nor PKD is involved in the cell death pathway, mediated by APP.

(A-C) F11 cells, transfected with the empty pcDNA3.1/MycHis vector (vector) or pcDNA3.1/MycHis-V642I-APP (V642I-APP), were co-incubated with or without 1 μM DAPK1 inhibitor or 1 μM PKD inhibitors or DMSO for 48 h. The co-incubation was started at 24 h after transfection. At 72 h after transfection, the cells were harvested for Trypan blue exclusion assays (A) and WST-8 assays (B). The cell lysates were subjected to SDS-PAGE and
immunoblot analysis with aa antibody against APP (C). ***p < 0.001; **p < 0.01; n.s., not significant

**Figure 9. Netrin1 binds to APP and inhibits TGFβ2-induced neuronal cell death via APP.**

(A). Conditioned media, derived from the cells that were transfected with the empty pEF1/MycHis vector (vector) or pEF1/MycHis-mNetrin1 (mouse netrin1 C-terminally tagged with MycHis), were collected for pull-down with TALON beads (Beads) for the preparation of 6xHis-tagged mNetrin1. In parallel, F11 cells were transfected with the empty pHA vector (vector), pRK5-wtUNC5C (wtUNC5C-HA), or pHA-wtAPP (wtAPP-HA). At 24 h after transfection, the cell lysates were prepared from the cells. The washed TALON beads capturing mNetrin1-MycHis (mNetrin1) or control (vector) were then mixed with one of these cell lysates. The whole mixtures were incubated at 4°C overnight and then washed. The final beads (Pull-down) as well as the beads and the cell lysates (Inputs) were used for immunoblot analysis with a monoclonal antibody against HA. Similar results were obtained in two independent experiments. (B-C) F11 cells, transfected with the empty pFLAG vector (vector) or pFLAG-wtAPP (wtAPP), were co-incubated with 1 µM mNetrin1 or BSA together with 20 nM TGFβ2 or PBS. This co-incubation was started at 24 h after transfection. At 72 h after transfection, they were harvested for Trypan blue exclusion assays (B). The cell lysates were subjected to SDS-PAGE and immunoblot analysis with an antibody against APP (C). ***p < 0.001; n.s., not significant

**Figure 10. Schematic illustration of the proposed T835M-UNC5C- and V642I-APP-induced neuronal death-signaling pathways.**

The UNC5C-induced death signaling pathway is mediated by DAPK1, PKD, ASK1, JNK, NADPH oxidase, and caspases (Figs. 1-8), while the APP-induced death signaling pathway is mediated by Go, Rac1/Cdc42, ASK1, MAPKK, JNK, NADPH oxidase, and caspases (9-13). The T835M mutation of UNC5C and a London-type mutation of APP, V642I, intensify each death signaling (Fig. 1)(9-13). CLSP binds to the heterotrimeric Humanin receptor and induces expression of SH3BP5 which inhibits the UNC5C- and APP-mediated death signaling by inhibiting JNK (Fig. 2)(21, 23, 24, 26). Netrin1 binds to UNC5C and inhibits the UNC5C-induced death signaling (Fig. 1). Netrin1 binds to APP and partially inhibits the APP-induced death signaling and reduces the production of Aβ (Fig. 9).
Figure 1

A. Trypan Blue Test

B. WST-8 Assay

C. WB (anti-HA)

D. Trypan Blue Test

E. WST-8 Assay

F. WB (anti-HA)
Figure 2

A) Trypan Blue Test

B) WST-8 Assay

C) WB (anti-HA)

D) Trypan Blue Test

E) Calcein Assay

F) WB (anti-HA)
Figure 3

A. Trypan Blue Test

B. WST-8 Assay

C. Abs 450 nm

D. Input IP with anti-myc

Myc DAPK1

Myc vector

wt UNC5C-HA

wt UNC5C

Δ DD

WB (anti-HA)

WB (anti-myc)
Figure 4

A

Trypan Blue Test

B

WST-8 Assay

C

WB(anti-HA)

D

Trypan Blue Test

E

WB(anti-HA)

WB(anti-DAPK1+anti-PKD)
Figure 5

A

Trypan Blue Test

Cell Mortality [%]

B

WB (anti-HA)

T835M - UNC5C

dnJNK
dnASK1
vector

100
90
80
70
60
50
40
30
20
10
0

( kDa )

120
140
160
180
200
220
240

vector
dnJNK
dnASK1
T835M - UNC5C

n.s.

***

Figure 5

A B
Figure 6

A

Trypan Blue Test

B

caPKD

vector

WB(anti-PKD)

endo PKD

capPKD

WB(anti-HA)

C

FLAG-JNK1α1

WB(anti-HA)

Input

JNK Kinase Assay

WB(anti-phospho JNK)

WB(anti-FLAG)

WB(anti-phospho c-Jun)

WB(anti-HA)

WB(anti-phospho c-Jun)

WB(anti-FLAG)

n.s.

***

***

***
Figure 7

A  Trypan Blue Test

B  WST-8 Assay

C  WB(anti-HA)
Figure 8

A  Trypan Blue Test

B  WST-8 Assay

C  WB(anti-APP)

n.s.

***

**

0 10 20 30 40 50 60 70 80 90 100

Cell Mortality [%]

0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

Abs450nm

DMSO  DAPKinhibitor  PKDinhibitor  vector  DMSO  DAPKinhibitor  PKDinhibitor  V642I-APP

n.s.

n.s.

n.s.
Figure 9

A

Input

Pull-down

Beads

140
100
75

(kDa)

BSA
mNetrin1
PBS

pFLAG vector

140
100
75

(kDa)

BSAmNetrin1
TGFβ2

PBS
wtAPP

WB(anti-HA)

mNetrin1-HA

WB(anti-myc)

B

Trypan Blue Test

Cell mortality [%]

0
10
20
30
40
50
60
70
80
90
100

0.5
1
n.s.

pFLAG vector wtAPP

C

pFLAG vector wtAPP

PBS TGFβ2 PBS TGFβ2

WB(anti-APP)

n.s.***

n.s.***

n.s.***
An Alzheimer’s disease-linked rare mutation potentiates netrin receptor uncoordinated-5C-induced signaling that merges with amyloid β precursor protein signaling
Yuichi Hashimoto, Yuka Toyama, Shinya Kusakari, Mikiro Nawa and Masaaki Matsuoaka

J. Biol. Chem. published online April 11, 2016

Access the most updated version of this article at doi: 10.1074/jbc.M115.698092

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts